| thalidomide / Generic mfg. |
NCT03896737 / 2018-002089-37: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara |
|
|
| Active, not recruiting | 2 | 401 | Europe, RoW | Daratumumab plus Velcade Cyclophosphamide Dexamethasone, Velcade Thalidomide Dexamethasone | European Myeloma Network, EMN Research Italy | Multiple Myeloma | 05/24 | 02/25 | | |
ChiCTR2000040718: A single arm Trial of Ixazomib plus Thalidomide and dexamethasone as Frontline Therapy in Patients With transplant-ineligible multiple myeloma |
|
|
| Not yet recruiting | 2 | 77 | | ITd for 6 cycles as intinal treatment and IT maintenance therapy for a maximum of 26 cycles(24 months). | Peking University People's Hospital; Peking University People’s Hospital, Takeda (China) International Trading Co.,Ltd | Multiple myeloma | | | | |
NCT00869232: UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission |
|
|
| Active, not recruiting | 2 | 90 | US | Velcade, PS-341, Melphalan, Alkeran, Thalidomide, Thalomid, Dexamethasone, Decadron, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Vp-16, Vepesid | University of Arkansas | Multiple Myeloma | 10/24 | 10/24 | | |
NCT00871013: Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy |
|
|
| Active, not recruiting | 2 | 160 | US | Melphalan, Alkeran, Velcade, Bortezomib, PS-341, Thalidomide, Thalomid, Dexamethasone, Decadron, Cisplatin, Platinol, CDDP, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Vepesid, VP-16 | University of Arkansas | Myeloma | 12/24 | 12/24 | | |
ChiCTR2300070448: Efficacy and safety of cetuximab plus FOLFIRI/FOLFOX combined with thalidomide in first-line treatment of RAS and BRAF wild-type stage IV left colorectal cancer |
|
|
| Not yet recruiting | 2 | 18 | | cetuximab plus FOLFIRI/FOLFOX combined with thalidomide | The Third Affiliated Hospital of Chongqing Medical University; The Third Affiliated Hospital of Chongqing Medical University, Beijing Baikouen Charity Foundation | left colorectal cancer | | | | |
NCT03601806: Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection |
|
|
| Active, not recruiting | 2 | 26 | RoW | Laboratory Biomarker Analysis, Pomalidomide, 4-Amino thalidomide, Actimid, CC-4047, Imnovid, Pomalyst | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, Montefiore Medical Center, University of Stellenbosch, Weill Medical College of Cornell University, University of California, Los Angeles | Human Immunodeficiency Virus 1 Positive, Skin Kaposi Sarcoma | 11/24 | 01/26 | | |
ChiCTR2200061195: Clinical study of thalidomide combined with chemotherapy in the treatment of relapsed or refractory yolk sac tumor in children |
|
|
| Not yet recruiting | 2 | 20 | | Oral thalidomide combined with TGA chemotherapy | Affiliated Cancer Hospital of Shandong First Medical University; Affiliated Cancer Hospital of Shandong First Medical University, Qilu Special Fund of Shandong Medical Association | yolk sac tumor | | | | |
ChiCTR2200066232: A multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical trial of thalidomide in the treatment of patients with transfusion-dependent β-thalassemia |
|
|
| Not yet recruiting | 2 | 144 | | 25mg/d, participant takes the medicine after dinner and the dose can be further adjusted if any adverse reactions are observed ;50mg/d, participant takes the medicine after dinner and the dose can be further adjusted if any adverse reactions are observed ;75mg/d, participant takes the medicine after dinner and the dose can be further adjusted if any adverse reactions are observed ;Placebo, participant takes the placebo after dinner and the dose can be further adjusted if any adverse reactions are observed. | Wuzhou Gongren Hospital; Wuzhou Gongren Hospital, Special funds | Thalassaemia | | | | |
NCT04941937: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM |
|
|
| Recruiting | 2 | 90 | RoW | Selinexor, ATG-010/KPT-330, Thalidomide, fǎn yìng tíng, Lenalidomide, Revlimid, An xian, Pomalidomide, POMALYST, Dexamethasone, Dex | Juan Du | Multiple Myeloma | 12/25 | 12/25 | | |
| Recruiting | 2 | 100 | Europe, US, RoW | Bevacizumab, Avastin, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, Etoposide phosphate, Cytarabine | Medical University of Vienna | Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent | 04/26 | 04/26 | | |
NCT05198856: Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC |
|
|
| Not yet recruiting | 1/2 | 106 | NA | Thalidomide Combined With Chemotherapy and Monotherapy, Fanyingting | Qilu Hospital of Shandong University | Gastric Cancer Metastatic to Liver | 03/24 | 12/24 | | |
NCT04891744: Selinexor in Combination With Thalidomide and Dexamethasone in RRMM |
|
|
| Not yet recruiting | 1/2 | 48 | RoW | Selinexor, ATG-010, Thalidomide, fǎn yìng tíng, Dexamethasone, Dex | Li Zheng | Multiple Myeloma | 12/24 | 12/24 | | |
| Completed | 1 | 27 | | Muti-dose Thalidomide ;Muti-dose Thalidomide and Diclofenac sodium enteric-coated tablets | Chinese PLA General Hospital; Changzhou Pharmaceutical Factory, Changzhou Pharmaceutical Factory | Ankylosing Spondylitis | | | | |
EQUULEUS, NCT01998971: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma |
|
|
| Completed | 1 | 240 | Europe, US | Daratumumab, Velcade, Pomalidomide, Dexamethasone, Melphalan, Prednisone, Thalidomide, Diphenhydramine, Acetaminophen, Carfilzomib, Lenalidomide, Montelukast | Janssen Research & Development, LLC | Multiple Myeloma | 01/19 | 01/24 | | |
|
|
|
|
|
|
|
|
|
|
NCT06098014: Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia |
|
|
| Completed | 1 | 60 | RoW | Thalidomide Capsules, Placebo | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Transfusion-dependent Thalassemia | 02/24 | 02/24 | | |
NCT01661400: Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors |
|
|
| Completed | 1 | 14 | US | Metronomic Cyclophosphamide, Cytoxan®, CPM, Thalidomide, Thalomid® | Washington University School of Medicine | Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Retinoblastoma | 12/23 | 12/23 | | |
ChiCTR2200060742: Effects of thalidomide combined with Camrelizumab on the incidence and efficacy of RCCEP in patients with non-small cell lung cancer |
|
|
| Not yet recruiting | 1 | 100 | | Thalidomide combined with carrilizhu | The Third Affiliated Hospital of Shandong First Medical University; The Third Affiliated Hospital of Shandong First Medical University, self-funded | reactive cutaneous capillary endothelial proliferation | | | | |
ChiCTR-ONRC-13003502: A multi-center, prospective, non-randomized clinical study of bortezomib / thalidomide, cyclophosphamide and dexamethasone combined with autologous hematopoietic stem cell transplantation in patients with de novo advanced multiple myeloma |
|
|
| Recruiting | N/A | 400 | | Chemotherapy ;Chemotherapy plus ASCT ;Chemotherapy ;Chemotherapy plus ASCT | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Self-financing | Multiple Myeloma | | | | |
ChiCTR2000037257: Long term efficacy and safety of thalidomide in the treatment of mild to moderate recurrent aphthous ulcer |
|
|
| Recruiting | N/A | 100 | | Oral thalidomide for two months ;Nil | Xinhua Hospital Affiliated to Medical College of Shanghai Jiaotong University; Xinhua Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shenkang group clinical research Youth Project | Recurrent aphthous ulcer | | | | |
| Completed | N/A | 1500 | | DMARDs ;biological agent ;thalidomide | Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University; Xijing Hospital, Fourth Military Medical University, Xijing Hospital, Fourth Military Medical University | Ankylosing spondylitis | | | | |
ChiCTR-TRC-12002335: Thalidomide with Etanercept combination therapy for tumor cachexia: an open label randomized controlled trial |
|
|
| Completed | N/A | 354 | | Thalidomide ;Thalidomide combined with Etanercept ;Etanercept | Shuyang People's Hospital; Level of the institution：, self-funded | tumor cachexia | | | | |
ChiCTR-IOR-15006635: A multi center clinical trail of the new traditional Chinese drug Pai-neng-da capsule in the treatment of myelodysplastic syndrome. |
|
|
| Not yet recruiting | N/A | 100 | | Pai-neng-da capsule 3 capsules a day two times + Andriol capsule 80 mg a day two times + thalidomide 100mg every night a + need transfusion symptomatic and supportive treatment ;Andriol capsule 80 mg a day two times + thalidomide 100mg every night a + need transfusion symptomatic and supportive treatment | Ningbo First Hospital; Ningbo First Hospital, Traditional Chinese Medicine administrationn of Zhejiang Provincial | myelodysplastic syndrome. | | | | |
| No Longer Available | N/A | | US | CC-2001, Thalidomide, Thaliomid | Celgene | Dermatologic, Other | | | | |
ChiCTR-IPR-17012144: A pilot randomized controlled trial for comparing CDA-II in Combination With DT-PDCE versus DT-PDCE Alone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 50 | | Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4; Uroacitides Injection 300ml / d, D1-D7. ;Dexamethasone 40 mg / d, oral, 4 d; thalidomide 100-200 mg / d, D1-4; cisplatin 10 mg / m2, D1-4; Pegylated liposomal doxorubicin 40 mg / m2, D1; Cyclophosphamide 400mg / m2, D1-4; Etoposide 40mg / (m2d), D1-4 | Henan Cancer Hospital; Henan Cancer hospital, Self-financing | Relapsed or Refractory Multiple Myeloma | | | | |
ChiCTR1800016194: Efficacy of cetuximab combined with thalidomide in the treatment of advanced colorectal cancer: a multicenter prospective randomized controlled clinical study |
|
|
| Not yet recruiting | N/A | 100 | | FOLFOX/FOLFORI(Every two weeks, 12 cycles)with cetuximab(250mg/m2）,added by thalidomide(50mg/d by 7 days, then added to 100mg/d without obvious complications) ;FOLFOX/FOLFORI(Every two weeks, 12 cycles)with cetuximab(250mg/m2） | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Xinhua Hospital, Changzhou Pharm; | Advanced colorectal cancer | | | | |
ChiCTR1800016335: An open, multicenter, randomized controlled, prospective clinical study of low-dose maintenance therapy with thalidomide as the main triple oral regimen for advanced hepatocellular carcinoma after TACE |
|
|
| Not yet recruiting | N/A | 136 | | low-dose maintenance therapy with thalidomide as the main triple oral regimen for advanced hepatocellular carcinoma after TACE ;TACE for advanced hepatocellular carcinoma | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, self-financing | Hepatocellular Carcinoma | | | | |
ChiCTR-INR-17013961: A pilot randomized controlled trial for comparing decitabine in Combination With DT-PDCE versus DT-PDCE Alone in Subjects with Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | N/A | 50 | | dexamethasone 40mg/d, po, 4d; thalidomide 100-200mg/d, D1-4; cis-platinum 10mg/m2, D1-4; liposomal doxorubicin hydrochloride 40 mg/m2, D1; cyclophosphamide 400mg/m2, D1-4; etoposide 40mg/(m2?d), D1-4; decitabine 10mg/d, D1-D5. 4 weeks/cycle, 3cycles in total ;dexamethasone 40mg/d, po, 4d; thalidomide 100-200mg/d, D1-4; cis-platinum 10mg/m2, D1-4; liposomal doxorubicin hydrochloride 40 mg/m2, D1; cyclophosphamide 400mg/m2, D1-4; etoposide 40mg/(m2?d), D1-4; 4 weeks/cycle, 3cycles in total | Henan Cancer Hospital; Henan Cancer hospital, Self-financing | Relapsed or Refractory Multiple Myeloma | | | | |
ChiCTR1800016003: Clinical observation of the first-line treatment of diffuse large B cell lymphoma with Thalidomide combined or sequential R-CHOP |
|
|
| Not yet recruiting | N/A | 80 | | Thalidomide+R-CHOP ;R-CHOP | The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, no | lymphoma | | | | |
ChiCTR1800015623: A prospective, randomized controlled clinical trial of thalidomide in the treatment of bone metastases with erythroid anemia |
|
|
| Recruiting | N/A | 280 | | Zoledronic acid + thalidomide ;Zoledronic acid | Shanghai Sixth People's hospital; Shanghai Sixth People's hospital, Changzhou SiYao pharmaceutical co., LTD | metastatic tumor of bone | | | | |
ChiCTR1900024662: Clinical study for thalidomide in the treatment of crizotinib-related diarrhea |
|
|
| Not yet recruiting | N/A | 12 | | Oral thalidomide 75mg ;Oral thalidomide 150mg | Department of Oncology, The Second People's Hospital of Yibin; Department of Oncology, The Second People's Hospital of Yibin, No funding | Crizotinib-related diarrhea | | | | |
ChiCTR1900021901: Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study |
|
|
| Completed | N/A | 30 | | Oral thalidomide | Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University, self-financing | central nervous system arteriovenous malformations | | | | |
ChiCTR2000031436: The effect of thalidomide on children with beta-thalassemia intermedia and major: a retrospective study |
|
|
| Not yet recruiting | N/A | 78 | | N/A | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, National Natural Science Foundation of China；Guangdong Natural Science Committee Project | Beta-thalassemia | | | | |
ChiCTR-IOR-17010695: The significance of minimal residual disease exmination on the multiple myeloma maintain treatment |
|
|
| Not yet recruiting | N/A | 600 | | thalidomide and Clarithromycin ;Observation | Shanghai Changzheng Hospital; Changzheng Hospital, National Natural Science Foundation of China. Project approval number 30828017 | Multiple myeloma | | | | |
ChiCTR1800015266: A Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Thalidomide in Adults and Adolescents with Transfusion-Dependent β-thalassemia Major/Intermediate |
|
|
| Not yet recruiting | N/A | 50 | | Thalidomide 100-150 mg qd po, adjusted according to adverse effects. ;Placebo 100-150 mg qd po | Wuzhou Gongren Hospital, Guangxi Zhuang Autonomous Region; Wuzhou Gongren Hospital, Guangxi Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region Science and Technology Department, Wuzhou Gongren Hospital | Thalassaemia | | | | |
ChiCTR1800015702: A Multicentric, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Thalidomide in Adults and Adolescents with Transfusion-Dependent β-thalassemia Major/Intermediate |
|
|
| Recruiting | N/A | 100 | | thalidomide 100-150 mg/time/day ;Placebo | Wuzhou Gongren Hospital, Guangxi Zhuang Autonomous Region; Wuzhou Gongren Hospital, Guangxi Zhuang Autonomous Region, Guangxi Zhuang Autonomous Region Science and Technology Department, Wuzhou Gongren Hospital | Thalassaemia | | | | |
ChiCTR-INR-17013467: Clinical Study on Treatment of Behcet Syndrome with Xiaoyao San in Traditional Chinese Medicine |
|
|
| Not yet recruiting | N/A | 60 | | ;Thalidomide | The First Affiliated Hospital of Heilongjiang Chinese Medicine Colledge; The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Self sponsored and department sponsored | Behcet's syndrome | | | | |
ChiCTR2000037172: Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease |
|
|
| Not yet recruiting | N/A | 120 | | Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets ;placebo + Thalidomide Tablets | Shanghai Traditional Chinese Medicine Hospital; Shanghai Traditional Chinese Medicine Hospital, Shanghai Shenkang Hospital Development Center | Behcet's Disease | | | | |
ChiCTR2100053515: A prospective, single-arm, single-center clinical study of the preliminary safety and efficacy of thalidomide in the treatment of refractory uremic pruritus |
|
|
| Not yet recruiting | N/A | 20 | | Thalidomide | Renji Hospital School of Medicine Shanghai Jiao Tong University ; Renji Hospital School of Medicine Shanghai Jiao Tong University, Enterprise funding | urmia pruritus | | | | |
ChiCTR2000035444: Efficacy and Safety of Low-dose Ruxoltinib Combined with Thalidomide, Prednisone, and Testosterone Decanoate (TPT) in Patients with Lower and Intermediate Risk Myelofibrosis ---a Single Arm, Multicenter, and Prospective Study |
|
|
| Not yet recruiting | N/A | 41 | | Low-dose Ruxoltinib Combined with Thalidomide, Prednisone, and Testosterone Decanoate (TPT) | The Sixth People's Hospital Affiliated to Shanghai Jiaotong University; Renji Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine, Self-financing | Myelofibrosis | | | | |
NCT05059613: Thalidomide With or Without Probiotics in Radioactive Oral Mucositis |
|
|
| Not yet recruiting | N/A | 40 | RoW | probiotics | Jiangxi Provincial Cancer Hospital | Oral Mucositis, Quality of Life | 12/22 | 12/22 | | |
ChiCTR2200066013: The effect of thalidomide on children with beta-thalassemia major: a retrospective study |
|
|
| Not yet recruiting | N/A | 21 | | N/A | Zigong First People's Hospital; Zigong First People's Hospital, the Key Science and Technology Project of Zigong | thalassemia | | | | |
ChiCTR1800014946: Thalidomide, Clarithromycin and Dexamethasone Regimen for Patients With Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | N/A | 37 | | Thalidomide, Clarithromycin and Dexamethasone | Bejing Chaoyang Hospital; Bejing Chaoyang Hospital, Key Medical Program of Full Sail Plan of Beijing Municipal Administration of Hospitals: Multiple Myeloma | Multiple Myeloma | | | | |
NCT06256627: The Maintenance Treatment of "ITIVA" in AML Patients |
|
|
| Recruiting | N/A | 130 | RoW | recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine | Henan Cancer Hospital | Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, Interferon-α-1b, Interleukin-2, Thalidomide, Venentoclax, Azacitidine | 03/25 | 05/27 | | |
| Recruiting | N/A | 83 | RoW | Bortezomib, Intervention Group | Hospital General de Mexico | Response, Acute Phase, Survivorship | 03/24 | 03/24 | | |
ChiCTR2100046657: Single-arm, multicenter, observational study of thalidomide, 5-HT3 receptor antagonist combined with dexamethasone regimen for the prevention of delayed vomiting caused by highly/moderately emetogenic chemotherapy in Hainan cancer patients |
|
|
| Recruiting | N/A | 250 | | Observational Study, No intervention | The Second Affiliated Hospital of Hainan Medical University; The Second Affiliated Hospital of Hainan Medical University, Self-raised | Chemotherapy-associated vomiting | | | | |
ChiCTR2100048178: Thalidomide alone or in combination of probiotics prospective prevention paclitaxel chemotherapy in patients with breast cancer-associated diarrhea, randomized, placebo-controlled, double-blind clinical study |
|
|
| Not yet recruiting | N/A | 230 | | Thalidomide ;Probiotics ;Combination | The Sixth Affiliated Hospital, Sun Yat-sen University; The Sixth Affiliated Hospital, Sun Yat-sen University, Funding for the 1010 project of the Sixth Affiliated Hospital, Sun Yat-sen University | Breast cancer | | | | |
| Not yet recruiting | N/A | 40 | NA | Thalidomide | Children's Hospital of Fudan University | Inflammatory Bowel Diseases | 12/25 | 12/26 | | |
| Recruiting | N/A | 120 | Europe | Usual Care | University of Nottingham, The Thalidomide Trust | Pain, Chronic, Pain | 09/24 | 12/24 | | |
ChiCTR2300067535: Clinical study of Tongdu Shujin decoction in the treatment of ankylosing spondylitis with cold-dampness obstruction type: Study protocol for a randomized controlled trial |
|
|
| Not yet recruiting | N/A | 80 | | Tongdu Shujin decoction ;Celecoxib capsules and thalidomide tablets | The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine, Self-selected subject | Ankylosing spondylitis | | | | |
ChiCTR2200055486: A prospective, single-arm, multicenter, exploratory clinical study of Selinexor combined with bortezomib, thalidomide, and dexamethasone (SPTD) in patients with relapsed and refractory multiple myeloma |
|
|
| Recruiting | N/A | 66 | | selinexor combined with bortezomib, thalidomide and dexamethasone | First Affiliated Hospital of Zhejiang University School of Medicine; First Affiliated Hospital of Zhejiang University School of Medicine, Self-raised | multiple myeloma | | | | |
ChiCTR2300072093: The efficacy and safety of Rotercept combined with thalidomide in the treatment of transfusion-dependent beta-thalassemia patients |
|
|
| Not yet recruiting | N/A | 36 | | Rotercept (0.6mg/kg) q3w s.c.+ Thalidomide 1.8mg/kg q12h p.o. ;Rotercept (1.25mg/kg) q3w s.c.+ Thalidomide 1.8mg/kg q12h p.o. ;Rotercept (1.25mg/kg) q3w s.c.+ Thalidomide 3.3mg/kg q12h p.o. | Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou Life Oasis Public Service Center | Transfusion dependent thalassemia | | | | |
MM-C01, ChiCTR2000035100: A prospective, single-arm, exploratory clinical study on the treatment of refractory and relapsed multiple myeloma (MM) patients with Chidamide combined with Thalidomide, Cyclophosphamide and Dexamethasone (TC2D) |
|
|
| Recruiting | N/A | 66 | | Chidamide combined with Thalidomide, Cyclophosphamide and Dexamethasone | The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University, Self-raised | Multiple Myeloma | | | | |
ChiCTR2200064230: A randomized controlled multi-center clinical study of Sanzi Huangshi No. 2 pills combined with thalidomide in the treatment of low-risk MDS |
|
|
| Not yet recruiting | N/A | 92 | | Thalidomide ;Sanzi Huangshi No.2 Pill Combined with Thalidomide | Shanghai municipal Hospital of Traditional Chinese Medicine，Shanghai University of Traditional Chinese Medicine; Shanghai municipal Hospital of Traditional Chinese Medicine，Shanghai University of Traditional Chinese Medicine, Shanghai Science and Technology Commission | Myelodysplastic Syndrome | | | | |
NCT05561049: Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma |
|
|
| Not yet recruiting | N/A | 120 | NA | Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens | The First Affiliated Hospital of Soochow University | Newly Diagnosed Multiple Myeloma | 09/24 | 09/25 | | |